Editas Medicine Inc

NASDAQ:EDITUnited States

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).

Contact Information

Headquarters

11 Hurley StCAMBRIDGE, MA, United States 02141-2110

Phone

617-401-9000

Fax

302-655-5049

Executives

Independent Chairman of the Board

Emma Reeve

President, Chief Executive Officer, Director

Gilmore O Neill

Chief Financial Officer, Executive Vice President

Erick Lucera

Chief People Officer, Executive Vice President

Linea Aspesi

Executive Vice President, Chief Technology Officer, Chief Business Officer

Bruce Eaton